EAU 2026: Updates in NMIBC

EAU 2026

12 - 16 Mar 2026

Published: 18 Mar 2026

Rating:

Save

Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra Masson-Lecomte

Dr Francesco Soria (Università di Torino, Torino, Italy), Prof Jonathan Aning (University of Bristol, Bristol, UK), Dr Antoni Vilaseca (Hospital Clínic de Barcelona, Barcelona, Spain), and Prof Alexandra Masson-Lecomte (Hôpital Henri Mondor, Créteil, France) discuss the latest updates in non muscle invasive bladder cancer from EAU 2026.

The panel explores key developments in risk stratification, focusing on how clinicians can better assess and categorize patients to guide treatment decisions.

They also clarify the clinical implications of prior Bacillus Calmette-Guérin exposure, including how to define and manage patients who are considered BCG-experienced.

The discussion then turns to current approaches for managing disease recurrence after BCG therapy, highlighting available treatment options and real-world decision-making challenges.

Finally, the experts share additional emerging data and insights that may shape the future management of non–muscle-invasive bladder cancer.

	Risk stratification in NMIBC, including approaches to assessing and categorising patient risk
	Management of disease recurrence following BCG therapy: current treatment options and clinical decision-making
	Final analysis of the phase 1 first-in-human study of erda-iDRS, an erdafitinib intravesical drug-releasing system, in patients with non–muscle-invasive bladder cancer harboring select FGFR alterations
	Financial and clinical implications of prior BCG exposure, including patients who are BCG-experienced
	Fluorescence cystoscopy and adjuvant optimized mitomycin-C in non-muscle invasive bladder cancer with high risk of recurrence – results from the prospective randomized FinnBladder 9 trial